Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CDX-1307

Vaccine (Peptide vaccine) · Immune activation · developed by Celldex Therapeutics

Phase 2 Most advanced trial (none active)

CLDX Developer

1 Registered trials

What is CDX-1307?

CDX-1307 is a vaccine given together with the immune adjuvants GM-CSF, Poly-ICLC and Resiquimod. It is studied in bladder cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Peptide vaccine)
Mechanism: Immune activation
Therapy area: Oncology
Developer: Celldex Therapeutics (CLDX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01094496	Phase 2	Bladder Cancer	Terminated	CLDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder Cancer

More from Celldex Therapeutics

Barzolvolimab Phase 3 CDX 0158 Phase 1 CDX-014 Phase 1 CDX-1140 Phase 2 CDX-301 Phase 2 CDX-3379 Phase 2 CDX-527 Phase 1 CDX-585 Phase 1 CDX-622 Phase 1 Glembatumumab Vedotin Phase 2 Keyhole Limpet Hemocyanin Phase 2 Rindopepimut Phase 2

Sources

ClinicalTrials.gov NCT01094496

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLDX page.

Follow CLDX, the company behind CDX-1307

See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLDX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z